SPARC receives positive top-line results from phase 3 trial for investigational drug

Sun Pharma Advanced Research Company (SPARC) on Wednesday said it has received positive top-line results from phase 3 trial for its investigational drug, SDN-037, for the treatment of inflammation and pain associated with ocular surgery. "SPARC reported positive top-line results from its phase 3 trial for its investigational drug, SDN-037, for the treatment of inflammation and pain associated with ocular surgery.

Sun Pharma Advanced Research Company (SPARC) on Wednesday said it has received positive top-line results from phase 3 trial for its investigational drug, SDN-037, for the treatment of inflammation and pain associated with ocular surgery. SPARC said its investigational drug met pre-specified primary and secondary endpoints. "SPARC reported positive top-line results from its phase 3 trial for its investigational drug, SDN-037, for the treatment of inflammation and pain associated with ocular surgery. The trial met its pre-specified primary and secondary objectives," the company said in a regulatory filing

The objective of the trial was to assess the efficacy and safety of SDN-037 in clearing the inflammation and pain, the company added

Shares of SPARC were trading 0.56 per cent higher at Rs 170.30 apiece on BSE.